Emcure Pharmaceuticals · NSE: EMCURE · BSE: 544210
Q2 FY26 results · Jul–Sep 2025
Emcure Pharmaceuticals reported revenue from operations of ₹2,269.82 crore (up 13.4% from Q2 FY25) and net profit of ₹251.37 crore (up 24.7% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,269.82 | 2,001.98 | +13.4% | 2,100.54 | +8.1% |
| Other income | 3.12 | 35.65 | −91.2% | 3.70 | −15.5% |
| Total income | 2,272.95 | 2,037.64 | +11.5% | 2,104.23 | +8.0% |
| Profit before tax | 341.42 | 273.41 | +24.9% | 290.76 | +17.4% |
| Net profit for the period | 251.37 | 201.55 | +24.7% | 214.79 | +17.0% |
| Attributable to shareholders of the company | 243.46 | 194.57 | +25.1% | 206.95 | +17.6% |
| EPS, basic (₹) | 12.85 | 10.33 | +24.4% | 10.92 | +17.7% |
| Net margin (%) | 11.1 | 10.1 | 10.2 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,260.60 | 1,104.63 | +14.1% | 1,096.57 | +15.0% |
| Other income | 22.75 | 54.93 | −58.6% | 21.52 | +5.7% |
| Total income | 1,283.36 | 1,159.56 | +10.7% | 1,118.10 | +14.8% |
| Profit before tax | 157.89 | 119.36 | +32.3% | 165.67 | −4.7% |
| Net profit for the period | 117.62 | 86.92 | +35.3% | 122.79 | −4.2% |
| EPS, basic (₹) | 6.21 | 4.62 | +34.4% | 6.48 | −4.2% |
| Net margin (%) | 9.3 | 7.9 | 11.2 |
Consolidated
- Filed with BSE
- 11 Nov 2025, 16:22 IST
- Board meeting
- 11 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Nov 2025, 16:22 IST
- Board meeting
- 11 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE